insulin aspart

(redirected from Novorapid)
Also found in: Medical, Wikipedia.

insulin as·part

 (ăs′pärt′)
n.
A rapid-acting insulin analog whose amino acid sequence differs from that of human insulin by the substitution of aspartic acid for proline in the B chain, used in the treatment of type 1 and type 2 diabetes.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Drugs like Sanofi 's Lantus, Merck's Janumet , Januvia, Eli Lily Co's Humalin, Humalog, Novo Nordisk's Novorapid, Novolog, Levemir, and Victoza and Novartis' Galvus are popular in Diabetes treatments.
Vaccines delivery devices are also increasingly used among diabetic patients to inject doses of insulin such as Novorapid and Lantus.
Academics at Liverpool University found that diabetes drug NovoRapid costs seven-anda-half times more in the US than in the UK.
Liverpool University research found that diabetes drug NovoRapid costs seven-and-ahalf times more in the US.
Other highly priced medicines are Novorapid (insulin) flexpen 5p from LE 350 to LE 472.5; Closol spray 40ml from LE12.75 to 15; Floxabact 500mg 5 tab from LE 10 to LE 14.75; Caldin Zinc susp 120ml from LE 10 to 16.5; and Bioprex 7.5mg 30 tab from LE 90 to LE 117.
Caption: Image A An 80-year-old patient taking NovoRapid with visual acuity of 6/12 and IOP of30mmHg presents for an eye examination.
Eleven patients were excluded from this study: 4 were from the NovoRapid group (group Asp) and 7 from Prandilin group (group Lis).
With respect to insulin classes, the compliance level was highest among the patients receiving Lantus insulin (95.58[+ or -]18.54%) and was lowest among those receiving NovoRapid insulin (85.71[+ or -]24.39%).
According to the company, Fiasp is an innovative formulation of insulin aspart that more closely matches the natural physiological insulin response of a person without diabetes, after a meal, compared with NovoRapid (conventional insulin aspart).
Fiasp is also claimed to have the option of a flexible dosing regimen (up to 20 minutes after starting a meal), without compromising overall glycaemic control, when compared to NovoRapid dosed at mealtime.
Many Key Biologics Losing Protection by 2020 Top 10 biologics total $79Bn sales globally Global Top 10 Biologics sales US Non US expiry date EU expiry by region Sales US date Adalimumab (Humira) 66% 34% 2016 2018 Insulin Glargine (Lantus) 77% 23% Expired Expired Etanercept (Enbrel) 66% 34% 2028 (extended) Expired Infliximab (Remicade) 57% 43% 2018 Expired Rituximab (Mabthera) 55% 45% 2018 Expired Bevacizumab (Avastin) 48% 52% 2020 2019 Trastuzumab (Herceptin) 41% 59% 2019 Expired Insulin Aspart (Novorapid) 78% 22% Expired Expired Glatiramer Acetate (Copaxone) 84% 16% Expired 2017 Pegfilgrastim (Neulasta) 84% 16% 2015 2017 Source: QuintilesIMS, MIDAS, MAT Q4 2015.
Her other medications including Penmix 30 50-unit mane, 40-unit nocte, NovoRapid 12 units at lunchtime, cholecalciferol, losartan, and dabigatran 110 mg bd were continued.